A Historic Milestone in Best Disease Research
For decades, individuals diagnosed with Best disease (Best vitelliform macular dystrophy) have faced a progressive loss of central vision with no available treatments to halt or reverse the condition. However, the therapeutic landscape has recently experienced a monumental shift. In late 2025, the first-ever clinical trial evaluating a gene therapy specifically designed for Best disease officially began, marking a new era of hope for the patient community.
Understanding the Investigational Therapy: OPGx-BEST1
The investigational treatment, known as OPGx-BEST1, is being developed by Opus Genetics, a clinical-stage gene therapy company focused on inherited retinal diseases. OPGx-BEST1 is designed to address the root cause of Best disease: mutations in the BEST1 gene.
How It Works
Best disease is typically an autosomal dominant condition, meaning that a single mutated copy of the BEST1 gene is sufficient to cause the disease. The mutated gene produces a dysfunctional bestrophin-1 protein that interferes with the normal function of the retinal pigment epithelium (RPE).
OPGx-BEST1 utilizes a specialized delivery vehicle, known as an adeno-associated virus (AAV) vector, to deliver a healthy, functional copy of the BEST1 gene directly to the cells of the retina. The goal is to provide the RPE cells with the correct instructions to produce normal bestrophin-1 protein, thereby restoring proper ion transport and fluid balance, and ultimately preserving vision.
The Phase 1/2 Clinical Trial Design
The initiation of the Phase 1/2 clinical trial follows clearance from the U.S. Food and Drug Administration (FDA) and represents the culmination of years of rigorous preclinical research.
Study Objectives
The primary objective of this early-stage trial is to evaluate the safety and tolerability of OPGx-BEST1 in human participants. Researchers will closely monitor patients for any adverse reactions or side effects associated with the treatment.
A secondary, but equally important, objective is to assess the preliminary efficacy of the gene therapy. Investigators will measure various aspects of visual function and retinal structure to determine if the treatment can stabilize or improve the condition.
Participant Enrollment
The trial is designed to enroll a small group of adult participants who have a confirmed genetic diagnosis of Best disease or other BEST1-related bestrophinopathies. The first participant was successfully dosed in November 2025, a landmark event celebrated by researchers and patient advocacy groups alike.
Early Promise and Future Outlook
While the trial is still in its early stages, initial reports presented at medical conferences in early 2026 have been encouraging. Preliminary data suggests that the therapy has been well-tolerated, with no significant safety concerns identified thus far. Furthermore, early observations hint at potential improvements in both visual function and retinal structure in treated individuals.
It is crucial to recognize that clinical trials are a multi-year process. The Phase 1/2 study will continue to monitor participants over an extended period to gather comprehensive data on the long-term safety and durability of the treatment. If successful, this trial will pave the way for larger, late-stage studies required for regulatory approval.
The launch of the OPGx-BEST1 clinical trial is a testament to the power of genetic research and the relentless pursuit of treatments for inherited retinal diseases. It represents a beacon of hope for families affected by Best disease, signaling that a future with preserved vision may finally be within reach.
*
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.